All three TruSight Oncology 500 assays are designed to identify key biomarkers in guidelines and clinical trials.
Assess key cancer biomarkers from FFPE tumor tissue with the TruSight Oncology 500 Assay.
Batch up to 192 samples at a time while using the same biomarkers and tissue type as the TruSight Oncology 500 assay.
Analyze circulating tumor DNA from plasma with the TruSight Oncology 500 ctDNA assay.
|TruSight Oncology 500 High-Throughput||TruSight Oncology 500||TruSight Oncology 500 ctDNA|
|Content Specifications||Targeted selection of DNA from 523 genes of interest, and RNA from 55 genes, for a total of 1.94Mb panel size.
• Immuno-oncology Biomarker Coverage: TMB and MSI
• Guideline Coverage: Broad coverage of key guidelines for multiple solid tumor types
• Clinical Trials Coverage: Over 600 clinical trials*
|Hands-On Time||Manual: ~10.5 hrs
Automated: ~2.5 hrs
|Input Quantity||40 ng DNA, 40-80 ng RNA (need at least 2 mm3 FFPE tissue)|
|Sample Throughput||16–192 samples per flow cell|
* Based on Pierian clinical knowledgebase, as of February 2023.
† NovaSeq 6000Dx System in RUO Mode requires a separate, stand-alone DRAGEN server for secondary analysis.
Fusion and splice variants as detected using TruSight Oncology 500 o the NextSeq 500 System. Numeric values represent the number of supporting reads for each sample at the indicated RNA input amount. Cut-off value for RNA fusions = 5; cut-off value for splice variants = 10.